FI65914C - Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a - Google Patents

Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a Download PDF

Info

Publication number: FI65914C
Authority: FI; Finland
Prior art keywords: weight; cyclosporin; composition; compositions; pharmaceutical composition
Prior art date: 1978-03-07

Application number

FI790640A

Other languages

English (en)

Finnish (fi)

Other versions

FI65914B (fi

FI790640A (fi

Inventor

Thomas Cavanak

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-03-07

Filing date

1979-02-26

Publication date

1984-08-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25690510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI65914(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1978-03-07 Priority claimed from CH246178A external-priority patent/CH636013A5/de

1979-02-26 Application filed by Sandoz Ag filed Critical Sandoz Ag

1979-09-08 Publication of FI790640A publication Critical patent/FI790640A/fi

1984-04-30 Application granted granted Critical

1984-04-30 Publication of FI65914B publication Critical patent/FI65914B/fi

1984-08-10 Publication of FI65914C publication Critical patent/FI65914C/fi

Links

PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title description 24
229930105110 Cyclosporin A Natural products 0.000 title description 24
108010036949 Cyclosporine Proteins 0.000 title description 24
239000008194 pharmaceutical composition Substances 0.000 title description 9
239000000203 mixture Substances 0.000 description 28
229960001265 ciclosporin Drugs 0.000 description 21
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
108090000765 processed proteins & peptides Proteins 0.000 description 13
239000000243 solution Substances 0.000 description 11
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 8
239000004006 olive oil Substances 0.000 description 8
235000008390 olive oil Nutrition 0.000 description 8
150000002148 esters Chemical class 0.000 description 5
238000000034 method Methods 0.000 description 4
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
241000282472 Canis lupus familiaris Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000035622 drinking Effects 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
239000007787 solid Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
241000282560 Macaca mulatta Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
235000013361 beverage Nutrition 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
229940049964 oleate Drugs 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
229940126701 oral medication Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
238000005809 transesterification reaction Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
108010036941 Cyclosporins Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241001149960 Tolypocladium inflatum Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
229940095353 oral granules Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
-1 polyethylene Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000010465 pomace olive oil Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000007789 sealing Methods 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000006104 solid solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
238000013112 stability test Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
150000003649 tritium Chemical class 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/27—Cyclic peptide or cyclic protein

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Dispersion Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

FI790640A 1978-03-07 1979-02-26 Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a FI65914C (fi)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
CH246178A CH636013A5 (en)	1978-03-07	1978-03-07	More readily absorbable pharmaceutical composition
CH246178		1978-03-07
CH863478		1978-08-14
CH863478		1978-08-14

Publications (3)

Publication Number	Publication Date
FI790640A FI790640A (fi)	1979-09-08
FI65914B FI65914B (fi)	1984-04-30
FI65914C true FI65914C (fi)	1984-08-10

Family

ID=25690510

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI790640A FI65914C (fi)	1978-03-07	1979-02-26	Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a

Country Status (27)

Country	Link
US (1)	US4388307A (it)
JP (1)	JPS54132223A (it)
AR (1)	AR223667A1 (it)
AT (1)	AT375828B (it)
AU (1)	AU528714B2 (it)
CA (1)	CA1139667A (it)
CY (1)	CY1285A (it)
DD (1)	DD142149A5 (it)
DE (1)	DE2907460A1 (it)
DK (1)	DK154539C (it)
ES (1)	ES478295A1 (it)
FI (1)	FI65914C (it)
FR (1)	FR2419072A1 (it)
GB (1)	GB2015339B (it)
HK (1)	HK48585A (it)
IE (1)	IE48016B1 (it)
IL (1)	IL56790A (it)
IT (1)	IT1115038B (it)
KE (1)	KE3516A (it)
MY (1)	MY8500134A (it)
NL (2)	NL187260C (it)
NO (2)	NO152635C (it)
NZ (1)	NZ189819A (it)
PH (1)	PH15159A (it)
PT (1)	PT69309A (it)
SE (1)	SE445174B (it)
SG (1)	SG14785G (it)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3167014D1 (en) *	1980-02-14	1984-12-13	Sandoz Ag	A method for the total synthesis of cyclosporins and novel cyclosporins
DE3224619A1 (de) *	1981-07-14	1983-05-19	Freund Industrial Co., Ltd., Tokyo	Orale pharmazeutische zusammensetzung
US4525339A (en) *	1982-10-15	1985-06-25	Hoffmann-La Roche Inc.	Enteric coated oral dosage form
EP0127426A1 (en) *	1983-05-23	1984-12-05	Takeda Chemical Industries, Ltd.	Percutaneous pharmaceutical compositions for external use
US5639724A (en) *	1984-07-24	1997-06-17	Sandoz Ltd.	Cyclosporin galenic forms
GB8903804D0 (en) *	1989-02-20	1989-04-05	Sandoz Ltd	Improvements in or relating to organic compounds
US5411951A (en) *	1984-10-04	1995-05-02	Monsanto Company	Prolonged release of biologically active somatotropin
US5474980A (en) *	1984-10-04	1995-12-12	Monsanto Company	Prolonged release of biologically active somatotropins
US4727035A (en) *	1984-11-14	1988-02-23	Mahoney Walter C	Immunoassay for cyclosporin
US4576645A (en) *	1984-12-06	1986-03-18	Block Drug Co., Inc.	Whipped gel composition
JPS61280435A (ja) *	1985-04-04	1986-12-11	Kanji Takada	サイクロスポリン類のリンパ指向性製剤
US4775659A (en) *	1985-08-19	1988-10-04	Eli Lilly And Company	Injectable semi-solid formulations
GB8524421D0 (en) *	1985-10-03	1985-11-06	Boots Co Plc	Therapeutic agents
US4764381A (en) *	1985-12-06	1988-08-16	Key Pharmaceuticals, Inc.	Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
US5118493A (en) *	1986-05-02	1992-06-02	Brigham And Women's Hospital	Composition having reduced nephrotoxocity comprising a fatty acid containing component and cyclosporine
EP0305400B1 (en) *	1986-05-02	1992-09-09	Brigham And Women's Hospital	A composition having reduced nephrotoxicity comprising a fatty acid containing component and cyclosporine
KR880012221A (ko) *	1987-04-13	1988-11-26	사노 가즈오	에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물
JP2577049B2 (ja) *	1987-06-04	1997-01-29	三共株式会社	シクロスポリン製剤
GB8717300D0 (en) *	1987-07-22	1987-08-26	Nat Res Dev	Cyclosporins
US4839342A (en) *	1987-09-03	1989-06-13	University Of Georgia Research Foundation, Inc.	Method of increasing tear production by topical administration of cyclosporin
AU620048B2 (en) *	1987-09-03	1992-02-13	University Of Georgia Research Foundation, Inc., The	Ocular cyclosporin composition
KR920003601B1 (ko) *	1987-09-03	1992-05-04	유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드	점안 싸이클로스포린(cyclosporin)의 조성물
US5756450A (en) *	1987-09-15	1998-05-26	Novartis Corporation	Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
DE3830494B4 (de) *	1987-09-15	2006-05-18	Novartis Ag	Wasserlösliche Monoester als Solubilisatoren für pharmakologische Wirkstoffe und pharmazeutische Hilfsstoffe
HU205010B (en) *	1987-09-15	1992-03-30	Sandoz Ag	Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity
EP0327280B1 (en) *	1988-01-29	1992-03-18	Sankyo Company Limited	Cyclosporin compositions
CH679119A5 (it) *	1988-05-13	1991-12-31	Sandoz Ag
HU201567B (en) *	1988-07-21	1990-11-28	Gyogyszerkutato Intezet	Process for production of intravenous medical compositions containing cyclosphorin
KR0148748B1 (ko) *	1988-09-16	1998-08-17	장 크라메르, 한스 루돌프 하우스	사이클로스포린을 함유하는 약학조성물
US5342625A (en) *	1988-09-16	1994-08-30	Sandoz Ltd.	Pharmaceutical compositions comprising cyclosporins
US6007840A (en) *	1988-09-16	1999-12-28	Novartis Ag	Pharmaceutical compositions comprising cyclosporins
GR1000466B (el) *	1989-01-28	1992-07-30	Sandoz Ag	Μεθοδος παρασκευης νεων φαρμακευτικων μορφων κυκλοσπορινης.
BE1003009A5 (fr) *	1989-02-09	1991-10-22	Sandoz Sa	Nouvelles compositions pharmaceutiques a base de cyclosporines.
US7081445B2 (en)	1989-02-20	2006-07-25	Novartis Ag	Cyclosporin galenic forms
US4996193A (en) *	1989-03-03	1991-02-26	The Regents Of The University Of California	Combined topical and systemic method of administration of cyclosporine
US5540931A (en) *	1989-03-03	1996-07-30	Charles W. Hewitt	Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
HU208491B (en) *	1990-11-27	1993-11-29	Gyogyszerkutato Intezet	Process for producing oral pharmaceutical composition containing cyclosporin
GB9113872D0 (en) *	1991-06-27	1991-08-14	Sandoz Ag	Improvements in or relating to organic compounds
US6262022B1 (en)	1992-06-25	2001-07-17	Novartis Ag	Pharmaceutical compositions containing cyclosporin as the active agent
GB9208712D0 (en) *	1992-04-22	1992-06-10	Sandoz Ltd	Pharmaceutical compositions containing cyclosporin derivates
ES2098739T3 (es)	1992-05-13	1997-05-01	Sandoz Ltd	Composiciones oftalmicas conteniendo una cyclosporin.
EP0570829B1 (de) *	1992-05-18	2001-04-25	CicloMulsion AG	Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur intravenösen Applikation sowie Verfahren zu ihrer Herstellung
US5637317A (en) *	1992-05-18	1997-06-10	Dietl; Hans	Pharmaceutical preparation containing cyclosporin(s) for oral administration and process for producing same
CZ278863B6 (en) *	1992-09-07	1994-07-13	Galena	Medicinal preparations with n-methylated cyclic undecapeptides
EP0589843B1 (en)	1992-09-25	2001-11-28	Novartis AG	Pharmaceutical compositions containing cyclosporins
NZ247516A (en) *	1993-04-28	1995-02-24	Bernard Charles Sherman	Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
CH686761A5 (de)	1993-05-27	1996-06-28	Sandoz Ag	Galenische Formulierungen.
US20020099067A1 (en) *	1993-07-08	2002-07-25	Ulrich Posanski	Pharmaceutical compositions for sparingly soluble therapeutic agents
DE69426408T2 (de)	1993-09-28	2001-07-12	Novartis Ag, Basel	Herstellung von Weichgelatinekapseln
DE4340781C3 (de) *	1993-11-30	2000-01-27	Novartis Ag	Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
KR0146671B1 (ko) *	1994-02-25	1998-08-17	김충환	사이클로스포린-함유 분말 조성물
NZ270145A (en) *	1994-03-01	1996-08-27	Lilly Co Eli	Non-aqueous pharmaceutical formulation for oral administration comprising water-insoluble active agent, fatty acid solubilising agent, an oil and a surface active agent
SE518578C2 (sv) *	1994-06-15	2002-10-29	Gs Dev Ab	Lipidbaserad komposition
JPH10504291A (ja) *	1994-07-22	1998-04-28	ジー．ディー．サールアンドカンパニー	自己乳化性ドラッグデリバリーシステム
PT789580E (pt)	1994-11-03	2002-09-30	Novartis Ag	Formulacoes de ciclosporina para administracao oral com composicao simples e alta biodisponibilidade e processo para a sua producao
US5603951A (en) *	1994-11-09	1997-02-18	Hanmi Pharm. Ind. Co., Ltd.	Cyclosporin-containing soft capsule compositions
HU215966B (hu) *	1994-11-21	1999-07-28	BIOGAL Gyógyszergyár Rt.	Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
KR0167613B1 (ko) *	1994-12-28	1999-01-15	한스 루돌프 하우스, 니콜 케르커	사이클로스포린-함유 연질캅셀제 조성물
KR100239799B1 (ko) *	1995-01-21	2000-02-01	손경식	경구투여용 사이클로스포린 에이 고체미셀분산체, 이의 제조 방법 및 고형제제
US6696413B2 (en) *	1995-06-16	2004-02-24	Hexal Ag	Pharmaceutical preparation with cyclosporin A
SE504582C2 (sv) *	1995-07-06	1997-03-10	Gs Dev Ab	Cyklosporinkomposition baserad på en L2-fas
US5766629A (en)	1995-08-25	1998-06-16	Sangstat Medical Corporation	Oral cyclosporin formulations
US5962019A (en) *	1995-08-25	1999-10-05	Sangstat Medical Corporation	Oral cyclosporin formulations
KR100294935B1 (ko) *	1995-08-25	2001-07-12	프란시스 제이 메이어	경구용 시클로스포린 제제
US5834017A (en) *	1995-08-25	1998-11-10	Sangstat Medical Corporation	Oral cyclopsporin formulations
US5827822A (en) *	1996-03-25	1998-10-27	Sangstat Medical Corporation	Cyclosporin a formulations as nanoparticles
DE19549852B4 (de)	1995-11-29	2009-06-04	Novartis Ag	Cyclosporin enthaltende Präparate
US5858401A (en)	1996-01-22	1999-01-12	Sidmak Laboratories, Inc.	Pharmaceutical composition for cyclosporines
US5958876A (en) *	1996-06-19	1999-09-28	Novartis Ag	Cyclosporin-containing pharmaceutical compositions
KR980008239A (ko) *	1996-07-26	1998-04-30	김충환	사이클로스포린-함유 약학적 조성물
US5798333A (en) *	1996-09-17	1998-08-25	Sherman; Bernard C.	Water-soluble concentrates containing cyclosporins
DE29824679U1 (de) *	1997-01-30	2002-03-28	Novartis Ag, Basel	Pharmazeutische Zusammensetzungen
CA2284000C (en) *	1997-03-12	2012-01-03	Abbott Laboratories	Hydrophilic binary systems for the administration of cyclosporine
CA2285983A1 (en)	1997-04-29	1998-11-05	Bernard Charles Sherman	Emulsion preconcentrate comprising a cyclosporin and acetylated monoglyceride
NZ314702A (en) *	1997-04-29	1998-07-28	Bernard Charles Sherman	Pharmaceutical composition comprising a cyclosporin in a solvent system of acetylated monoglycerides and a surfactant and optionally a hydrophilic solvent
US6008191A (en) *	1997-09-08	1999-12-28	Panacea Biotec Limited	Pharmaceutical compositions containing cyclosporin
US6187747B1 (en)	1997-09-08	2001-02-13	Panacea Biotech Limited	Pharmaceutical composition comprising cyclosporin
IN188719B (it) *	1997-09-08	2002-11-02	Panacea Biotec Ltd
US6346511B1 (en)	1997-09-08	2002-02-12	Panacea Biotec Limited	Pharmaceutical composition comprising cyclosporin
US6028067A (en) *	1997-12-05	2000-02-22	Chong Kun Dang Corp.	Cyclosporin-containing microemulsion preconcentrate composition
KR19990047897A (ko) *	1997-12-05	1999-07-05	김충환	사이클로스포린 함유 약학적 조성물
US6063762A (en) *	1997-12-05	2000-05-16	Chong Kun Dang Corp.	Cyclosporin-containing microemulsion preconcentrate composition
NZ512287A (en)	1998-12-11	2002-12-20	Pharmasolutions Inc	Pharmaceutical compositions comprising a lipophilic drug in a propylene glycol ester of a higher fatty acid carrier, where 60% of the ester is a monoester
DE69939335D1 (de)	1998-12-30	2008-09-25	Dexcel Ltd	Dispergierbares konzentrat zur verabreichung von cyclosporin
US6761903B2 (en)	1999-06-30	2004-07-13	Lipocine, Inc.	Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6294192B1 (en)	1999-02-26	2001-09-25	Lipocine, Inc.	Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) *	1999-06-30	2001-07-31	Lipocine Inc.	Clear oil-containing pharmaceutical compositions
ES2251985T3 (es) *	1999-03-24	2006-05-16	R.P. Scherer Technologies, Inc.	Particula granulada para mejorar la solubilidad acuosa de farmacos, y su procedimiento de preparacion.
US6383471B1 (en)	1999-04-06	2002-05-07	Lipocine, Inc.	Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6057289A (en) *	1999-04-30	2000-05-02	Pharmasolutions, Inc.	Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
US6982281B1 (en) *	2000-11-17	2006-01-03	Lipocine Inc	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6458383B2 (en)	1999-08-17	2002-10-01	Lipocine, Inc.	Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6309663B1 (en)	1999-08-17	2001-10-30	Lipocine Inc.	Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US7732404B2 (en)	1999-12-30	2010-06-08	Dexcel Ltd	Pro-nanodispersion for the delivery of cyclosporin
GB0000313D0 (en)	2000-01-10	2000-03-01	Astrazeneca Uk Ltd	Formulation
CN1431896A (zh) *	2000-04-04	2003-07-23	盐野义制药株式会社	含有高脂溶性药物的油性组合物
WO2001097832A1 (de) *	2000-06-21	2001-12-27	Audit Institute For Medical Services And Quality Assurance Gmbh	Pharmazeutische zubereitungen enthaltend cyclosporine und neutralöle
WO2002022158A1 (en) *	2000-09-18	2002-03-21	Rpg Life Sciences Limited	Selfemulsifiable formulation having enhanced bioabsorption and immunosuppression activities
JP2005500314A (ja) *	2001-06-21	2005-01-06	ファイザー・プロダクツ・インク	コレステロールエステル転送蛋白インヒビターの自己乳化性製剤
CN1259049C (zh)	2001-07-06	2006-06-14	苏坎波公司	包含白介素－2抑制剂和抗菌剂的局部给药组合物
JP2005506990A (ja) *	2001-10-19	2005-03-10	アイソテクニカインコーポレーテッド	新規のシクロスポリン類似体のマイクロエマルションプレコンセントレート
EP1458405A1 (en) *	2001-11-21	2004-09-22	Sucampo AG	Use of fk506 and analogues for treating allergic diseases
US20050129718A1 (en) *	2001-12-20	2005-06-16	Sherman Bernard C.	Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant
KR20030065831A (ko) *	2002-02-01	2003-08-09	주식회사 태평양	사이클로스포린을 함유한 지속 방출형 약학적 조성물
US6828301B2 (en) *	2002-02-07	2004-12-07	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for hepatitis C viral protease inhibitors
GB2391471B (en) *	2002-08-02	2005-05-04	Satishchandra Punambhai Patel	Pharmaceutical compositions
GB2391473B (en) *	2002-08-02	2004-07-07	Satishchandra Punambhai Patel	Pharmaceutical compositions
GB2391472B (en) *	2002-08-02	2004-12-08	Satishchandra Punambhai Patel	Pharmaceutical compositions
KR100507771B1 (ko) *	2002-11-08	2005-08-17	한미약품 주식회사	난용성 감기약 활성 성분의 경구투여용 조성물 및 그의제조 방법
US7842791B2 (en) *	2002-12-19	2010-11-30	Nancy Jean Britten	Dispersible pharmaceutical compositions
US6979672B2 (en)	2002-12-20	2005-12-27	Polichem, S.A.	Cyclosporin-based pharmaceutical compositions
US20040150061A1 (en) *	2003-01-30	2004-08-05	Hsin Chung Hsien	Package structure of a photosensor
ES2496102T3 (es) *	2003-03-28	2014-09-18	Sigmoid Pharma Limited	Forma de dosificación oral sólida que contiene microcápsulas sin fisuras
US20050059583A1 (en)	2003-09-15	2005-03-17	Allergan, Inc.	Methods of providing therapeutic effects using cyclosporin components
TW200517114A (en)	2003-10-15	2005-06-01	Combinatorx Inc	Methods and reagents for the treatment of immunoinflammatory disorders
CA2546347A1 (en)	2003-11-21	2005-06-09	Combinatorx, Incorporated	Methods and reagents for the treatment of inflammatory disorders
DE102004038980A1 (de) *	2004-08-10	2006-02-23	Cognis Deutschland Gmbh & Co. Kg	Antibeschlagmittel für Kunststoffe
ATE413165T1 (de) *	2004-09-27	2008-11-15	Sigmoid Pharma Ltd	Mikrokapseln mit einem methylxanthin und einem kortikosteroid
US7135455B2 (en) *	2004-11-15	2006-11-14	Allergan, Inc	Methods for the therapeutic use of cyclosporine components
US7151085B2 (en) *	2004-11-15	2006-12-19	Allergan, Inc.	Therapeutic methods using cyclosporine components
PL1885342T3 (pl) *	2005-03-21	2016-10-31		Inhibitor krystalizacji i jego zastosowanie w kapsułkach żelatynowych
US7288520B2 (en) *	2005-07-13	2007-10-30	Allergan, Inc.	Cyclosporin compositions
US20070015693A1 (en) *	2005-07-13	2007-01-18	Allergan, Inc.	Cyclosporin compositions
US7297679B2 (en) *	2005-07-13	2007-11-20	Allergan, Inc.	Cyclosporin compositions
US7202209B2 (en)	2005-07-13	2007-04-10	Allergan, Inc.	Cyclosporin compositions
US7276476B2 (en) *	2005-07-13	2007-10-02	Allergan, Inc.	Cyclosporin compositions
US20070015691A1 (en) *	2005-07-13	2007-01-18	Allergan, Inc.	Cyclosporin compositions
US7501393B2 (en)	2005-07-27	2009-03-10	Allergan, Inc.	Pharmaceutical compositions comprising cyclosporins
US9839667B2 (en)	2005-10-14	2017-12-12	Allergan, Inc.	Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) *	2005-10-14	2010-06-29	Gregg Feinerman	Prevention and treatment of ocular side effects with a cyclosporin
EP2218442A1 (en)	2005-11-09	2010-08-18	CombinatoRx, Inc.	Methods, compositions, and kits for the treatment of ophthalmic disorders
WO2008122966A2 (en) *	2007-04-04	2008-10-16	Sigmoid Pharma Limited	A pharmaceutical composition of tacrolimus
CA2686234A1 (en) *	2007-05-04	2008-11-13	Allergan, Inc.	Use of cyclosporines in the treatment of patients with intraocular lenses
GB2451811A (en)	2007-08-09	2009-02-18	Ems Sa	Delivery composition for solubilising water-insoluble pharmaceutical active ingredients
TW200932240A (en) *	2007-10-25	2009-08-01	Astellas Pharma Inc	Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
CA2749141A1 (en)	2009-01-08	2010-07-15	Allergan, Inc.	Cyclosporine compositions for enhancing nail growth
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
US20110009339A1 (en)	2009-04-14	2011-01-13	Allergan, Inc	Method of treating blurred vision and other conditions of the eye with cyclosporin compositions
WO2010133609A2 (en)	2009-05-18	2010-11-25	Sigmoid Pharma Limited	Composition comprising oil drops
CN102470103B (zh)	2009-07-07	2016-09-07	贝林格尔.英格海姆国际有限公司	用作丙型肝炎病毒蛋白酶抑制剂的药物组合物
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
HUE044591T2 (hu)	2011-03-11	2019-11-28	Beth Israel Deaconess Medical Ct Inc	Anti-CD40 antitestek és alkalmazásuk
EP2763650A2 (en)	2011-10-05	2014-08-13	Allergan, Inc.	Compositions for enhancing nail health
AU2012318823A1 (en)	2011-10-05	2014-04-24	Allergan, Inc.	Compositions for enhancing nail health
GB201319791D0 (en)	2013-11-08	2013-12-25	Sigmoid Pharma Ltd	Formulations
US20170246187A1 (en)	2014-08-28	2017-08-31	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
DK3215127T3 (da)	2014-11-07	2021-02-01	Sublimity Therapeutics Ltd	Sammensætninger omfattende cyclosporin
CN109069621B (zh)	2015-09-04	2022-09-06	普里玛托普医疗股份有限公司	人源化抗-cd40抗体及其用途
JPWO2017047299A1 (ja) *	2015-09-15	2017-12-21	富士フイルム株式会社	注射用液剤組成物
CA3078723A1 (en)	2016-11-28	2018-05-31	Nachiappan Chidambaram	Oral testosterone undecanoate therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1274354A (fr) *	1956-03-10	1961-10-27		Agents tensio-actifs obtenus à partir de triglycérides et polyéthylène glycol
GB1110875A (en) *	1964-12-11	1968-04-24	Glaxo Lab Ltd	Compositions containing procaine penicillins
FR94740E (fr) *	1967-10-25	1969-10-24	Rhone Poulenc Sa	Nouveaux cyclopeptides et leur préparation.
NL167323C (nl) *	1970-09-26	1981-12-16	Organon Nv	Werkwijze ter bereiding van een psychofarmacologisch preparaat.
ES396746A1 (es) *	1971-11-06	1974-12-01	Gallardo Antonio Sa	Nuevo procedimiento de fabricacion de suspensiones establesidoneas para antibioticos.
CH574247A5 (en) *	1972-02-17	1976-04-15	Ciba Geigy Ag	Oily, injectable peptide/aluminium alkanoate compsns - - with prolonged duration of activity
JPS4891218A (it) *	1972-03-06	1973-11-28
AR207116A1 (es) *	1973-03-28	1976-09-15	Ciba Geigy Ag	Procedimiento para preparar nuevas dotriacontapeptidoamidas
DE2463138C2 (de) *	1973-12-06	1984-07-05	Sandoz-Patent-GmbH, 7850 Lörrach	Das Antibiotikum Cyclosporin B (S 7481/F-2), seine Herstellung und Verwendung
GB1547164A (en) *	1975-08-14	1979-06-06	Beecham Group Ltd	Veterinary compositions
CH614931A5 (it) *	1975-11-04	1979-12-28	Sandoz Ag
DE2555481C3 (de) *	1975-12-10	1985-10-03	Sandoz-Patent-GmbH, 7850 Lörrach	Herstellung stabiler Tropflösungen von hydrierten Ergotalkaloiden
DE2819094A1 (de) *	1977-05-10	1978-11-23	Sandoz Ag	Cyclosporin-derivate, ihre verwendung und herstellung

1979
- 1979-02-26 DE DE19792907460 patent/DE2907460A1/de active Granted
- 1979-02-26 FI FI790640A patent/FI65914C/fi not_active IP Right Cessation
- 1979-02-26 SE SE7901683A patent/SE445174B/sv not_active IP Right Cessation
- 1979-02-27 IT IT48152/79A patent/IT1115038B/it active Protection Beyond IP Right Term
- 1979-02-27 FR FR7904989A patent/FR2419072A1/fr active Granted
- 1979-02-27 NO NO790661A patent/NO152635C/no unknown
- 1979-02-28 DK DK086079A patent/DK154539C/da not_active IP Right Cessation
- 1979-03-02 GB GB7907395A patent/GB2015339B/en not_active Expired
- 1979-03-02 CY CY1285A patent/CY1285A/xx unknown
- 1979-03-02 NL NLAANVRAGE7901703,A patent/NL187260C/xx active Protection Beyond IP Right Term
- 1979-03-05 ES ES478295A patent/ES478295A1/es not_active Expired
- 1979-03-05 AT AT0163779A patent/AT375828B/de not_active IP Right Cessation
- 1979-03-05 IL IL56790A patent/IL56790A/xx unknown
- 1979-03-05 PT PT69309A patent/PT69309A/pt unknown
- 1979-03-05 NZ NZ189819A patent/NZ189819A/en unknown
- 1979-03-06 DD DD79211409A patent/DD142149A5/de not_active IP Right Cessation
- 1979-03-06 PH PH22254A patent/PH15159A/en unknown
- 1979-03-06 CA CA000322853A patent/CA1139667A/en not_active Expired
- 1979-03-06 AU AU44862/79A patent/AU528714B2/en not_active Expired
- 1979-03-07 JP JP2722879A patent/JPS54132223A/ja active Granted
- 1979-03-07 AR AR275732A patent/AR223667A1/es active
- 1979-08-08 IE IE704/79A patent/IE48016B1/en not_active IP Right Cessation
1982
- 1982-02-09 US US06/347,276 patent/US4388307A/en not_active Expired - Lifetime
1985
- 1985-02-27 SG SG147/85A patent/SG14785G/en unknown
- 1985-03-22 KE KE3516A patent/KE3516A/xx unknown
- 1985-06-20 HK HK485/85A patent/HK48585A/xx not_active IP Right Cessation
- 1985-12-30 MY MY134/85A patent/MY8500134A/xx unknown
1993
- 1993-07-02 NL NL930135C patent/NL930135I1/nl unknown
1994
- 1994-12-28 NO NO1994028C patent/NO1994028I1/no unknown

Also Published As

Publication number	Publication date
FR2419072A1 (fr)	1979-10-05
NO152635B (no)	1985-07-22
NL187260C (nl)	1991-08-01
MY8500134A (en)	1985-12-31
KE3516A (en)	1985-04-19
JPS54132223A (en)	1979-10-15
DK86079A (da)	1979-09-08
FR2419072B1 (it)	1983-04-22
AU4486279A (en)	1979-09-13
SE7901683L (sv)	1979-09-08
DK154539C (da)	1989-05-16
IT7948152A0 (it)	1979-02-27
DD142149A5 (de)	1980-06-11
IE790704L (en)	1979-09-07
FI65914B (fi)	1984-04-30
FI790640A (fi)	1979-09-08
IL56790A0 (en)	1979-05-31
NL930135I1 (nl)	1993-11-01
NZ189819A (en)	1984-05-31
NO790661L (no)	1979-09-10
HK48585A (en)	1985-06-28
GB2015339B (en)	1982-09-15
NO1994028I1 (no)	1994-12-28
GB2015339A (en)	1979-09-12
AU528714B2 (en)	1983-05-12
CY1285A (en)	1985-07-05
US4388307A (en)	1983-06-14
SE445174B (sv)	1986-06-09
SG14785G (en)	1985-08-16
IL56790A (en)	1982-01-31
PH15159A (en)	1982-08-24
ATA163779A (de)	1984-02-15
AR223667A1 (es)	1981-09-15
NL7901703A (nl)	1979-09-11
DE2907460C2 (it)	1990-09-27
DE2907460A1 (de)	1979-09-13
PT69309A (fr)	1979-04-01
IT1115038B (it)	1986-02-03
AT375828B (de)	1984-09-10
NO152635C (no)	1985-10-30
JPS627891B2 (it)	1987-02-19
CA1139667A (en)	1983-01-18
DK154539B (da)	1988-11-28
ES478295A1 (es)	1979-05-16
IE48016B1 (en)	1984-09-05

Publication	Publication Date	Title
FI65914C (fi)	1984-08-10	Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
KR100257841B1 (ko)	2000-09-01	사이클로스포린-함유약학적조성물
KR0131064B1 (ko)	1998-04-17	사이클로스포린 함유 약학 조성물
US5614491A (en)	1997-03-25	Liquid preparations containing cyclosporin and process for preparing same
RU2126263C1 (ru)	1999-02-20	Фармацевтическая композиция, содержащая производное циклоспорина, способ ее получения
US20020165134A1 (en)	2002-11-07	Pharmaceutical compositions containing cyclosporins
KR19990062736A (ko)	1999-07-26	사이클로스포린 함유 고형마이크로에멀젼을 포함하는 약학적조성물
Kahan	1984	Cyclosporine: a powerful addition to the immunosuppressive armamentarium
WO1990008537A1 (en)	1990-08-09	Pharmaceutical compositions for oral administration
HU182920B (en)	1984-03-28	Process for preparing stable pharmaceutical compositions containing cyclosporin
Golbaekdal et al.	1994	Effects of rapamycin on renal hemodynamics, water and sodium excretion, and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide, and vasopressin in pigs
KR19990062580A (ko)	1999-07-26	사이클로스포린-함유 마이크로에멀젼 예비농축액 조성물
EP0199992B1 (en)	1990-08-29	Adsorption-resistant peptide composition and use of benzalkonium or benzethonium chloride in the preparation thereof
JPS6345366B2 (it)	1988-09-09
Ju et al.	2012	Sirolimus conversion in liver transplant recipients with calcineurin inhibitor-induced complications: efficacy and safety
de Waal et al.	1992	Effects of subcutaneous versus intravenous administration of cyclosporin A on rat thymic histology and pharmacokinetics
Sandberg et al.	1994	Acute effects of different immunosuppressive drugs on pancreatic, islet, renal, and arterial hepatic blood flow in anesthetized rats
JPS631923B2 (it)	1988-01-14
Tibell et al.	1994	Cyclosporin A in fat emulsion carriers: studies on the immunosuppressive potential, using the heterotopic heart transplant model in rats
KR19990047897A (ko)	1999-07-05	사이클로스포린 함유 약학적 조성물
SA89100046B1 (ar)	2005-04-17	التركيبات الصيدلية المشتملة على السيكلوسبورينات cycclosporins
KR19990066706A (ko)	1999-08-16	사이클로스포린-함유 마이크로에멀젼 예비농축액 조성물

Legal Events

Date	Code	Title	Description
1979-02-26	MA	Patent expired
1997-08-27	PC	Transfer of assignment of patent	Owner name: NOVARTIS AG
2004-08-31	MA	Patent expired	Owner name: NOVARTIS AG